HIV INFECTION DUE TO CLOTTING FACTOR CONCENTRATES--RESULTS OF THE SSP

从1987年至今，血清转化监测项目 提供了监测人类传播艾滋病毒风险的手段， 免疫缺陷病毒（HIV）的凝血因子浓缩物。 一 美国有131家血友病治疗中心 定期联系，并收集患者艾滋病毒检测数据。 迄今为止，9496例患者中有4366例（46.0%）报告为 血清阳性，并确定了37个新的血清转化。 九 这些人符合CDC的血清转化标准， 集中注意力 9例血清转化均不是由于浓缩物引起的 它已经被处理过抗病毒， 已接受爱滋病病毒抗体测试。 我们的研究结果表明，有一个 受影响的患者群体中血清阳性率较高，但 目前可用凝血因子导致艾滋病毒感染的风险 浓度极低。

Between 1987 and the present, the Seroconversion Surveillance Project has provided the means to monitor the risk of transmission of human immunodeficiency virus (HIV) by clotting factor concentrates. One hundred and thirty-one hemophilia treatment centers in the United States are regularly contacted and data on HIV testing of patients collected. To date, 4366 (46.0%) of 9496 patients have been reported to be seropositive, and thirty-seven new seroconversions identified. Nine of these have met the CDC criteria for seroconversion while taking factor concentrate. None of the nine seroconversions were due to concentrates that had been treated to inactivate viruses and made from plasma that had been tested for HIV antibody. Our results indicate that there is a high prevalence of seropositivity in affected patient groups, but that the risk of HIV infection from currently available clotting factor concentrates is extremely low.